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State Medicaid programs may bear a large portion of the
costs of Alzheimer's disease (AD), since they are the ma-
jor public payers for nursing home care. Recent data on
current spending by Medicaid for these patients are not
available.
OBJECTIVE: To document Medicaid spending in Cali-
fornia for persons with AD.
METHODS: This study was based on enrollment and
claims data for a 10% random sample of Medi-Cal recip-
ients 60+ years of age with Medicaid claims in 1995
(N = 62,450). Using a prevalence-based cost-of-illness
methodology, the cost of AD was estimated as the differ-
ence in average annual costs between persons with AD
and/or dementia, and an age- and sex-matched compari-
son cohort. Dementia was included with AD, since the
latter is difficult to diagnose, and may be coded more
broadly as dementia in an administrative database. Mul-
tivariate analyses were undertaken to control for differ-
ences in factors other than age and sex, including cornor-
bid conditions.
RESULTS: A total of 2,575 patients with AD and/or de-
mentia were identified, a prevalence of 4.1 %. From the
59,875 remaining recipients, 2,575 matched controls were
randomly selected. Several comorbid conditions were found
to be more common in the group with AD and/or demen-
tia. After adjustment, average annual payments were
found to be $7,700 higher for the AD/dementia cohort
($14,500 versus $6,800 for the comparison cohort, p <
0.01), 90% of which represented nursing home costs.
CONCLUSIONS: A diagnosis of AD and/or dementia is
associated with substantially higher Medicaid expendi-
tures. Annual excess spending for AD and/or dementia
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for the Medi-Cal program may be as high as $200 mil-
lion, or 10% of all expenditures for elderly recipients.
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The atypical antipsychotic agent olanzapine became
available for use at the Denver VA Medical Center late in
1996. Acquisition costs are significant and warrant eco-
nomic analysis.
OBJECTIVE: The purpose of this study is to examine the
impact of olanzapine therapy on costs of care for patients
at this medical center.
METHODS: A total of 59 patients receiving olanzapine
were identified from pharmacy databases. Of these pa-
tients, 25 received the drug for at least 6 months. Data
were compiled for psychiatry-related prescriptions, clinic
visits, and inpatient stays. All cost comparisons reported
are for the 6-month time periods before and after initia-
tion of olanzapine therapy. Costs for prescriptions reflect
drug acquisition costs. Costs for clinic visits and inpatient
stays were calculated using average unit costs. A paired
t-test was used to compare means.
RESULTS: The following per-patient results were ob-
tained: mental health clinic visits decreased by 32.3 (sd ±
44.4, p = 0.001), hospital admissions fell by 0.6 (sd ±
0.9, p = 0.003), and average length of stay decreased by
19.5 days (sd ± 34.5, p = 0.009). The average number of
active prescriptions per patient increased from 3.4 to 3.5,
while the average cost per patient of those prescriptions
increased from $586 to $2,230. Total costs changed as
follows: pharmacy costs increased from $14,700 to
$55,800, costs for clinic visits and hospitalizations fell
from $131,100 to $93,100 and from $301,100 to
$90,700, respectively. Overall cost per patient decreased
from $17,900 to $9,600.
CONCLUSIONS: While an increase in pharmacy costs after
initiation of olanzapine therapy was seen, overall costs of
psychiatry-related care decreased in this patient population.
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